Zhejiang DiAn Diagnostics Co Asset Resilience Ratio

Latest as of March 2026: 3.61%

Zhejiang DiAn Diagnostics Co asset resilience ratio. Zhejiang DiAn Diagnostics Co (300244) has an Asset Resilience Ratio of 3.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300244 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥508.66 Million
≈ $74.43 Million USD Cash + Short-term Investments

Total Assets

CN¥14.08 Billion
≈ $2.06 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Zhejiang DiAn Diagnostics Co (2019–2025)

Asset resilience ratio of Zhejiang DiAn Diagnostics Co from 2019 to 2025. This chart shows how Zhejiang DiAn Diagnostics Co's Asset Resilience Ratio has changed over time. Read 300244 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang DiAn Diagnostics Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Zhejiang DiAn Diagnostics Co balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥508.66 Million 3.61%
Total Liquid Assets CN¥508.66 Million 3.61%

Asset Resilience Insights

  • Limited Liquidity: Zhejiang DiAn Diagnostics Co maintains only 3.61% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhejiang DiAn Diagnostics Co Industry Peers by Asset Resilience Ratio

Compare Zhejiang DiAn Diagnostics Co's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Diagnósticos da América S.A
SA:DASA3
Diagnostics & Research 10.42%
SMO ClinPlus Co. Ltd.
SHE:301257
Diagnostics & Research 15.78%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%

Zhejiang DiAn Diagnostics Co Asset Resilience Ratio by Year (2019–2025)

Zhejiang DiAn Diagnostics Co asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Zhejiang DiAn Diagnostics Co.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 3.08% CN¥444.45 Million
≈ $65.04 Million
CN¥14.42 Billion
≈ $2.11 Billion
+0.65pp
2024-12-31 2.44% CN¥384.59 Million
≈ $56.28 Million
CN¥15.79 Billion
≈ $2.31 Billion
+0.10pp
2023-12-31 2.33% CN¥418.30 Million
≈ $61.21 Million
CN¥17.94 Billion
≈ $2.63 Billion
+0.19pp
2022-12-31 2.14% CN¥450.09 Million
≈ $65.86 Million
CN¥21.06 Billion
≈ $3.08 Billion
-0.60pp
2021-12-31 2.74% CN¥427.22 Million
≈ $62.52 Million
CN¥15.59 Billion
≈ $2.28 Billion
+0.24pp
2020-12-31 2.50% CN¥310.26 Million
≈ $45.40 Million
CN¥12.40 Billion
≈ $1.81 Billion
-0.23pp
2019-12-31 2.73% CN¥293.24 Million
≈ $42.91 Million
CN¥10.75 Billion
≈ $1.57 Billion
--
pp = percentage points

About Zhejiang DiAn Diagnostics Co

SHE:300244 China Diagnostics & Research
Market Cap
$1.89 Billion
CN¥12.91 Billion CNY
Market Cap Rank
#6158 Global
#1158 in China
Share Price
CN¥20.66
Change (1 day)
+5.09%
52-Week Range
CN¥14.54 - CN¥29.50
All Time High
CN¥46.17
About

Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated… Read more